Journal article

A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings

DJ Jonker, LS Rosen, M Sawyer, G Wilding, C Noberasco, G Jayson, G Rustin, G McArthur, L Velasquez, S Galbraith

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2007


3559 Background: Brivanib is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling. Part A of this study defined an MTD of 800 mg qd (Abstract # 3051, ASCO 2006). Part B investigated expanded doses / schedules for safety, PK and PD. Methods: In Part B, sequential cohorts were treated with 320 mg qd, 800 mg 5 days on/2 off (800I), 800 mg qd (800C), or 400 mg bid. Available data are reported for pts treated at these doses in Part A + B. PK samples were obtained Days 1, 8 and 26. Tumor DCE- MRI parameters, transfer constant (Ktrans), area under the concentration-time curve - first 60 s post contrast injection (AUC60) were measured baseline X 2, Days 2, 8 a..

View full abstract

University of Melbourne Researchers

Citation metrics